Skip to content
Moojaz — موجز
Search
Menu
HomeRegionsMaghrebAfricaMiddle EastEuropeAsiaAmericasWorldSectionsPoliticsEconomySecurityHealthScienceTechnologyAIEnvironmentCultureSportsSearch
United Arab Emirates
File

Abu Dhabi: depemokimab and chronic rhinosinusitis

Published

This dossier follows the announced introduction of depemokimab at Burjeel Medical City for chronic rhinosinusitis with nasal polyps, distinguishing reported use from documented clinical outcomes.

Latest event : 1 key moments
Editorial principlesReport an error
A stethoscope.
Medical illustration; does not show the patient or treatment. Sprinno, CC0 https://creativecommons.org/publicdomain/zero/1.0/ ; unmodified. — Sprinno / Wikimedia Commons — CC0 1.0 https://creativecommons.org/publicdomain/zero/1.0/ — 28 février 2014, sans modification.

Where things stand

In an announcement carried on 6–7 November 2026, Burjeel says it administered the treatment to a 43-year-old patient. Its claimed regional first and the patient’s clinical progress have not been independently verified.

Browse the full timeline

Reported information

Burjeel announces depemokimab administration for rhinosinusitis with nasal polyps

Burjeel Medical City in Abu Dhabi says it has administered depemokimab to a patient with chronic rhinosinusitis with nasal polyps. The announcement, carried by WAM on 6 November 2026, describes the use as a Gulf first.

A stethoscope.
Medical illustration; does not show the patient or treatment. Sprinno, CC0 https://creativecommons.org/publicdomain/zero/1.0/ ; unmodified. — Sprinno / Wikimedia Commons — CC0 1.0 https://creativecommons.org/publicdomain/zero/1.0/ — 28 février 2014, sans modification.

According to the hospital, the 43-year-old Emirati patient had experienced persistent symptoms for more than five years despite two operations. Burjeel describes a subcutaneous injection with a six-month dosing interval, administered with support and oversight from Abu Dhabi’s Department of Health.

WAM and Al-Ittihad repeat information supplied by the hospital; they are not two independent clinical assessments. The announcement documents reported use without publishing follow-up that establishes this patient’s outcome. Regional priority remains Burjeel’s claim.

Sources 3